Cancers, Vol. 13, Pages 6272: The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma
Cancers, Vol. 13, Pages 6272: The Transmembrane Receptor TIRC7 Identifies a Distinct Subset of Immune Cells with Prognostic Implications in Cholangiocarcinoma
Cancers doi: 10.3390/cancers13246272
Authors:
Thomas Albrecht
Benjamin Goeppert
Fritz Brinkmann
Alphonse Charbel
Qiangnu Zhang
Johannes Schreck
Nina Wilhelm
Stephan Singer
Bruno C. Köhler
Christoph Springfeld
Arianeb Mehrabi
Peter Schirmacher
Anja A. Kühl
Monika N. Vogel
Holger Jansen
Nalân Utku
Stephanie Roessler
Cholangiocarcinoma (CCA) is a heterogeneous malignancy with a dismal prognosis. Therapeutic options are largely limited to surgery and conventional chemotherapy offers limited benefit. As immunotherapy has proven highly effective in various cancer types, we have undertaken a quantitative immunohistopathological assessment of immune cells expressing the immunoinhibitory T cell immune response cDNA 7 receptor (TIRC7), an emerging immunoinhibitory receptor, in a cohort of 135 CCA patients. TIRC7+ immune cells were present in both the tumor epithelia and stroma in the majority of CCA cases with the highest levels found in intrahepatic CCA. While intraepithelial density of TIRC7+ immune cells was decreased compared to matched non-neoplastic bile ducts, stromal quantity was higher in the tumor samples. Tumors exhibiting signet ring cell or adenosquamous morphology were exclusively associated with an intraepithelial TIRC7+ phenotype. Survival analysis showed intraepithelial ...
Source: Cancers - Category: Cancer & Oncology Authors: Thomas Albrecht Benjamin Goeppert Fritz Brinkmann Alphonse Charbel Qiangnu Zhang Johannes Schreck Nina Wilhelm Stephan Singer Bruno C. K öhler Christoph Springfeld Arianeb Mehrabi Peter Schirmacher Anja A. K ühl Monika N. Vogel Holger Jansen Nal ân Utk Tags: Article Source Type: research
More News: Bile | Bile Duct Cancer | Cancer | Cancer & Oncology | Chemotherapy | Cholangiocarcinoma | Immunotherapy | Study